Johnson & Johnson Innovation - JJDC, Inc. has filed a 13F-NT, detailing its institutional investment activities for the third quarter of 2026. This filing is significant as it provides insight into the company's investment strategies and holdings as of September 30, 2026. Such disclosures are crucial for maintaining transparency with stakeholders and the broader market.
Background
Johnson & Johnson Innovation - JJDC, Inc. is a subsidiary of Johnson & Johnson, focusing on advancing healthcare innovations. The company operates under the entity type 'other' and is registered with the SEC under CIK 0000924020. The filing history shows a consistent pattern of reporting, with recent filings including a Schedule 13G on October 15, 2026, and another 13F-NT on August 6, 2026.
What the Filing Says
The filing, dated October 26, 2026, does not provide specific details about the holdings or investment strategies. It is primarily a notice of the company's investment activities for the preceding quarter. The filing states, "Quarterly report filed by institutional managers, Notice." This indicates compliance with SEC regulations regarding institutional investment disclosures.
Impact
This filing may affect various stakeholders, including investors, analysts, and competitors in the investment management industry. By disclosing its investment activities, Johnson & Johnson Innovation - JJDC, Inc. allows others in the industry to assess its strategies and market positioning. This transparency can influence investor confidence and competitive dynamics within the sector.
What's Next
The filing does not say what happens next. However, stakeholders will likely await further disclosures or updates regarding the company's investment performance and strategies in upcoming filings.